Medium materiality6/10
Wedbush Reiterates Outperform on MoonLake Immunotherapeutics
Why it may matterVerify against the original reporting
Bullish analyst view, though the large implied upside is not independently supported by facts in this record.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wedbush reiterated Outperform with a $34 target versus the posted price of $13.51, implying substantial indicated upside. This is an analyst opinion, not a company announcement.
- Wedbush reiterated Outperform.
- $34 target versus $13.51 posted price.
Key facts
- 01
Target: $34
- 02
Posted price: $13.51
- 03
Analyst firm: Wedbush
- 04
Analyst: Yun Zhong
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.